The role of passive immunization in the age of SARS-CoV-2: an update

[1]  T. Lv,et al.  Treatment with convalescent plasma for COVID‐19 patients in Wuhan, China , 2020, Journal of medical virology.

[2]  W. Zhou,et al.  Clinical characteristics and immunosuppressant management of coronavirus disease 2019 in solid organ transplant recipients , 2020, American Journal of Transplantation.

[3]  D. Segev,et al.  Early impact of COVID-19 on transplant center practices and policies in the United States , 2020, American Journal of Transplantation.

[4]  L. Mao,et al.  Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. , 2020, JAMA neurology.

[5]  Wayne T. Nicholson,et al.  Deployment of convalescent plasma for the prevention and treatment of COVID-19. , 2020, The Journal of clinical investigation.

[6]  N. Vaninov.  In the eye of the COVID-19 cytokine storm , 2020, Nature Reviews Immunology.

[7]  Yan Peng,et al.  Effectiveness of convalescent plasma therapy in severe COVID-19 patients , 2020, Proceedings of the National Academy of Sciences.

[8]  Chang Moon.  Fighting COVID-19 exhausts T cells , 2020, Nature Reviews Immunology.

[9]  Linda A. Perkins,et al.  A novel treatment approach to the novel coronavirus: an argument for the use of therapeutic plasma exchange for fulminant COVID-19 , 2020, Critical Care.

[10]  P. Gallian,et al.  Collecting and evaluating convalescent plasma for COVID‐19 treatment: why and how? , 2020, Vox sanguinis.

[11]  Wen Jiang,et al.  How should we implement radiotherapy for cancer patients in China during the endemic period of COVID-19?☆ , 2020, Radiotherapy and Oncology.

[12]  J. Guarner,et al.  Convalescent Plasma to Treat COVID-19: Possibilities and Challenges. , 2020, JAMA.

[13]  Jing Yuan,et al.  Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. , 2020, JAMA.

[14]  Taojiao Wang,et al.  Clinical and immunologic features in severe and moderate Coronavirus Disease 2019. , 2020, The Journal of clinical investigation.

[15]  C. Wang,et al.  Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China , 2020, Annals of Oncology.

[16]  J. Tanne.  Covid-19: FDA approves use of convalescent plasma to treat critically ill patients , 2020, BMJ.

[17]  Steven Y. C. Tong,et al.  Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19 , 2020, Nature Medicine.

[18]  Li Zhang,et al.  Risk of COVID-19 for patients with cancer , 2020, The Lancet Oncology.

[19]  P. Mehta,et al.  COVID-19: consider cytokine storm syndromes and immunosuppression , 2020, The Lancet.

[20]  Yuan Shi,et al.  Convalescent plasma as a potential therapy for COVID-19 , 2020, The Lancet Infectious Diseases.

[21]  Jiyuan Zhang,et al.  Pathological findings of COVID-19 associated with acute respiratory distress syndrome , 2020, The Lancet Respiratory Medicine.

[22]  Su Hwan Lee,et al.  Use of Convalescent Plasma Therapy in Two COVID-19 Patients with Acute Respiratory Distress Syndrome in Korea , 2020, Journal of Korean medical science.

[23]  R. Kruse.  Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China , 2020, F1000Research.

[24]  M. Huber-Lang,et al.  Autophagy and ATP-induced anti-apoptosis in antigen presenting cells (APC) follows the cytokine storm in patients after major trauma , 2011, Journal of Cell Communication and Signaling.

[25]  J. Bosch,et al.  Psychologically adverse work conditions are associated with CD8+ T cell differentiation indicative of immunesenescence , 2009, Brain, Behavior, and Immunity.

[26]  L. Ziegler‐Heitbrock,et al.  The CD14+ CD16+ blood monocytes: their role in infection and inflammation , 2007, Journal of leukocyte biology.

[27]  E. Schneider.  Bullfight without killers: interferon rules pathology in HLH , 2004 .

[28]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[29]  P. Matzinger.  The Danger Model: A Renewed Sense of Self , 2002, Science.